Intermediate vancomycin susceptibility in a community-associated MRSA clone.
We describe a case of treatment failure caused by a strain of USA300 community-associated methicillin-resistant Staphylococcus aureus (MRSA) with intermediate susceptibility to vancomycin and reduced susceptibility to daptomycin. The strain was isolated from the bone of a 56-year-old man with lumbar osteomyelitis after a 6-week treatment course of vancomycin for catheter-associated septic thrombophlebitis.
Graber
Christopher J
CJ
Division of Infectious Diseases, University of California, San Francisco General Hospital, 94110, USA. christopher.graber@ucsf.edu
Wong
Margaret K
MK
Carleton
Heather A
HA
Perdreau-Remington
Françoise
F
Haller
Barbara L
BL
Chambers
Henry F
HF
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology; D017576:Daptomycin / Q000494:pharmacology; D006801:Humans; D008159:Lumbar Vertebrae / Q000382:microbiology; D008297:Male; D008712:Methicillin / Q000494:pharmacology*; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010019:Osteomyelitis / Q000188:drug therapy / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D013924:Thrombophlebitis / Q000188:drug therapy; D016896:Treatment Outcome; D014640:Vancomycin / Q000494:pharmacology* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D014640:Vancomycin; D017576:Daptomycin; D008712:Methicillin